Scientific article

Possibilités thérapeutiques actuelles des troubles anxieux généralisés

Published inRevue médicale suisse, vol. 6, no. 255, p. 1370-1374
Publication date2010

Among a variety of drugs used in the treatment of anxiety disorders, benzodiazepines and antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are at present the most established and prescribed. In fact, recent guidelines recommend the antidepressants SSRI and SNRI as well as pregabaline, a newly developed drug, as the 1st choice treatment in generalized anxiety disorder (GAD). However, antidepressants have several disadvantages (latency of onset of action, adverse effects and drug interactions) that should not be neglected. Pregabaline is a drug with a new mechanism of action. Clinical studies up to now indicate a rather rapid and efficient anxiolytic effect comparable to that of benzodiazepines, with no risk of abuse. Pregabaline has been recently introduced in Switzerland for the treatment of GAD.

  • Anti-Anxiety Agents/therapeutic use
  • Antidepressive Agents/therapeutic use
  • Anxiety Disorders/drug therapy
  • Humans
Citation (ISO format)
DELINI-STULA, Alexandra, BONDOLFI, Guido, HOLSBOER-TRACHSLER, Edith. Possibilités thérapeutiques actuelles des troubles anxieux généralisés. In: Revue médicale suisse, 2010, vol. 6, n° 255, p. 1370–1374.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation12/13/2013 10:41:00 AM
First validation12/13/2013 10:41:00 AM
Update time03/14/2023 8:44:12 PM
Status update03/14/2023 8:44:12 PM
Last indexation01/16/2024 8:33:21 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack